Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TOBI tobramycin inhalation solution: Phase II; marketed to treat P. aeruginosa infection in cystic fibrosis patients

PGNS said that Phase II testing in 74 subjects

Read the full 90 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE